Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.
Oncternal Therapeutics reports developments tied to its oncology drug-development portfolio and corporate transition. The company had developed novel oncology therapies including ONCT-534, a dual-action androgen receptor inhibitor for relapsed or refractory metastatic castration-resistant prostate cancer; ONCT-808, an autologous ROR1-targeting CAR T therapy for aggressive B-cell lymphoma; and zilovertamab, an investigational ROR1 monoclonal antibody.
Recurring news themes include clinical-study updates, safety and efficacy data, financial results, termination of clinical programs, strategic-alternative activity, asset sales and the wind-down of operations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.